Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon

Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon

Source: 
Forbes
snippet: 

Melbourne-based biotech company Mesoblast announced earlier this week that it’s begun enrolling up to 300 patients for a randomized, controlled study of its stem cell therapy remestemcel-L in the treatment of COVID-19 patients experiencing acute respiratory distress syndrome. Over 20 hospitals will participate in the study, which is anticipated to last 3-4 months.